FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4206932673> ?p ?o ?g. }

• W4206932673 endingPage "24" @default.
• W4206932673 startingPage "24" @default.
• W4206932673 abstract "<ns3:p><ns3:bold>Background:</ns3:bold> Many available medicines have been evaluated as potential repurposed treatments for coronavirus disease 2019 (COVID-19). We summarise the registered study landscape for 32 priority pharmacological treatments identified following consultation with external experts of the COVID-19 Clinical Research Coalition.</ns3:p><ns3:p> <ns3:bold>Methods:</ns3:bold> All eligible trial registry records identified by systematic searches of the World Health Organisation International Clinical Trials Registry Platform as of 26<ns3:sup>th</ns3:sup> May 2021 were reviewed and extracted. A descriptive summary of study characteristics was performed.</ns3:p><ns3:p> <ns3:bold>Results:</ns3:bold> We identified 1,314 registered studies that included at least one of the 32 priority pharmacological interventions. The majority (1,043, 79%) were randomised controlled trials (RCTs). The sample size of the RCTs identified was typically small (median (25<ns3:sup>th</ns3:sup>, 75<ns3:sup>th</ns3:sup> percentile) sample size = 140 patients (70, 383)), i.e. individually powered only to show very large effects. The most extensively evaluated medicine was hydroxychloroquine (418 registered studies). Other widely studied interventions were convalescent plasma (n=208), ritonavir (n=189) usually combined with lopinavir (n=181), and azithromycin (n=147). Very few RCTs planned to recruit participants in low-income countries (n=14; 1.3%). A minority of studies (348, 26%) indicated a willingness to share individual participant data. The living systematic review data are available at <ns3:ext-link xmlns:ns4=http://www.w3.org/1999/xlink ext-link-type=uri ns4:href=https://iddo.cognitive.city/cognitive/welcome>https://iddo.cognitive.city</ns3:ext-link></ns3:p><ns3:p> <ns3:bold>Conclusions:</ns3:bold> There are many registered studies planning to evaluate available medicines as potential repurposed treatments of COVID-19. Most of these planned studies are small, and therefore substantially underpowered for most relevant endpoints. Very few are large enough to have any chance of providing enough convincing evidence to change policies and practices. The sharing of individual participant data (IPD) from these studies would allow pooled IPD meta-analyses which could generate definitive conclusions, but most registered studies did not indicate that they were willing to share their data.</ns3:p>" @default.
• W4206932673 created "2022-01-26" @default.
• W4206932673 creator A5000491173 @default.
• W4206932673 creator A5002458341 @default.
• W4206932673 creator A5008319359 @default.
• W4206932673 creator A5011553720 @default.
• W4206932673 creator A5013064994 @default.
• W4206932673 creator A5022387174 @default.
• W4206932673 creator A5025994087 @default.
• W4206932673 creator A5030632030 @default.
• W4206932673 creator A5032913310 @default.
• W4206932673 creator A5036594289 @default.
• W4206932673 creator A5041516138 @default.
• W4206932673 creator A5043639661 @default.
• W4206932673 creator A5044015460 @default.
• W4206932673 creator A5053752410 @default.
• W4206932673 creator A5055903115 @default.
• W4206932673 creator A5057943388 @default.
• W4206932673 creator A5060614086 @default.
• W4206932673 creator A5061503739 @default.
• W4206932673 creator A5064221654 @default.
• W4206932673 creator A5068243180 @default.
• W4206932673 creator A5075565282 @default.
• W4206932673 creator A5077704469 @default.
• W4206932673 creator A5082079110 @default.
• W4206932673 creator A5083840660 @default.
• W4206932673 creator A5084217335 @default.
• W4206932673 creator A5084265195 @default.
• W4206932673 creator A5084802999 @default.
• W4206932673 creator A5089526191 @default.
• W4206932673 creator A5089964878 @default.
• W4206932673 date "2022-01-25" @default.
• W4206932673 modified "2023-09-27" @default.
• W4206932673 title "The fragmented COVID-19 therapeutics research landscape: a living systematic review of clinical trial registrations evaluating priority pharmacological interventions." @default.
• W4206932673 cites W2014453502 @default.
• W4206932673 cites W2032959055 @default.
• W4206932673 cites W2514040346 @default.
• W4206932673 cites W2801687149 @default.
• W4206932673 cites W3008531780 @default.
• W4206932673 cites W3014186302 @default.
• W4206932673 cites W3033756437 @default.
• W4206932673 cites W3090929175 @default.
• W4206932673 cites W3091868035 @default.
• W4206932673 cites W3105753785 @default.
• W4206932673 cites W3110466220 @default.
• W4206932673 cites W3111431752 @default.
• W4206932673 cites W3123893780 @default.
• W4206932673 cites W3127349317 @default.
• W4206932673 cites W3135646190 @default.
• W4206932673 cites W3136216231 @default.
• W4206932673 cites W4206805526 @default.
• W4206932673 doi "https://doi.org/10.12688/wellcomeopenres.17284.1" @default.
• W4206932673 hasPublicationYear "2022" @default.
• W4206932673 type Work @default.
• W4206932673 citedByCount "3" @default.
• W4206932673 countsByYear W42069326732022 @default.
• W4206932673 countsByYear W42069326732023 @default.
• W4206932673 crossrefType "journal-article" @default.
• W4206932673 hasAuthorship W4206932673A5000491173 @default.
• W4206932673 hasAuthorship W4206932673A5002458341 @default.
• W4206932673 hasAuthorship W4206932673A5008319359 @default.
• W4206932673 hasAuthorship W4206932673A5011553720 @default.
• W4206932673 hasAuthorship W4206932673A5013064994 @default.
• W4206932673 hasAuthorship W4206932673A5022387174 @default.
• W4206932673 hasAuthorship W4206932673A5025994087 @default.
• W4206932673 hasAuthorship W4206932673A5030632030 @default.
• W4206932673 hasAuthorship W4206932673A5032913310 @default.
• W4206932673 hasAuthorship W4206932673A5036594289 @default.
• W4206932673 hasAuthorship W4206932673A5041516138 @default.
• W4206932673 hasAuthorship W4206932673A5043639661 @default.
• W4206932673 hasAuthorship W4206932673A5044015460 @default.
• W4206932673 hasAuthorship W4206932673A5053752410 @default.
• W4206932673 hasAuthorship W4206932673A5055903115 @default.
• W4206932673 hasAuthorship W4206932673A5057943388 @default.
• W4206932673 hasAuthorship W4206932673A5060614086 @default.
• W4206932673 hasAuthorship W4206932673A5061503739 @default.
• W4206932673 hasAuthorship W4206932673A5064221654 @default.
• W4206932673 hasAuthorship W4206932673A5068243180 @default.
• W4206932673 hasAuthorship W4206932673A5075565282 @default.
• W4206932673 hasAuthorship W4206932673A5077704469 @default.
• W4206932673 hasAuthorship W4206932673A5082079110 @default.
• W4206932673 hasAuthorship W4206932673A5083840660 @default.
• W4206932673 hasAuthorship W4206932673A5084217335 @default.
• W4206932673 hasAuthorship W4206932673A5084265195 @default.
• W4206932673 hasAuthorship W4206932673A5084802999 @default.
• W4206932673 hasAuthorship W4206932673A5089526191 @default.
• W4206932673 hasAuthorship W4206932673A5089964878 @default.
• W4206932673 hasBestOaLocation W42069326731 @default.
• W4206932673 hasConcept C118552586 @default.
• W4206932673 hasConcept C126322002 @default.
• W4206932673 hasConcept C132379496 @default.
• W4206932673 hasConcept C142462285 @default.
• W4206932673 hasConcept C159047783 @default.
• W4206932673 hasConcept C2522874641 @default.
• W4206932673 hasConcept C27415008 @default.
• W4206932673 hasConcept C2776408679 @default.
• W4206932673 hasConcept C2777182164 @default.
• W4206932673 hasConcept C2779134260 @default.

• next